David Lamond - 19 May 2022 Form 4 Insider Report for Cortexyme, Inc. (QNCX)

Role
Director
Signature
/s/ Chris Lowe, as Attorney-in-Fact for David Lamond
Issuer symbol
QNCX
Transactions as of
19 May 2022
Net transactions value
$0
Form type
4
Filing time
23 May 2022, 20:09:08 UTC
Previous filing
17 Jun 2021
Next filing
23 May 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction QNCX Common Stock Award +200,002 +13% 1,734,722 19 May 2022 By David A. Lamond Trust dated 2006 F1, F2
holding QNCX Common Stock 1,847,109 19 May 2022 By Blue Devil Trust dated 12/03/2010 F3
holding QNCX Common Stock 301,829 19 May 2022 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On March 19, 2022, the Issuer completed acquisition (the "Merger") of Novosteo Inc. ("Novosteo"), pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of May 9, 2022, (the "Merger Agreement"), by and among the Issuer, Quince Merger Sub I, Inc., a wholly owned subsidiary of the Issuer, Quince Merger Sub II, LLC, a wholly owned subsidiary of the Issuer, Novosteo, and Fortis Advisors LLC, solely in its capacity as the securityholders' representative. Pursuant to the terms of the Merger Agreement, at the closing of the Merger, the shares held by the Reporting Person in Novosteo were automatically cancelled and converted into the right to receive shares of common stock of the Issuer.
F2 Mr. Lamond is the trustee of David A. Lamond Trust dated 2006 (the "2006 Trust") and holds sole voting and dispositive power with respect to the shares held of record by the 2006 Trust.
F3 Mr. Lamond is the trustee of Blue Devil Trust dated 12/03/2010 (the "Trust") and holds sole voting and dispositive power with respect to the shares held of record by the Trust.